Dr. Annie Zhang embarked on her academic journey with a strong foundation in medicine and public health, earning an MD and an MPH. Her dual degrees equipped her with a nuanced understanding of clinical medicine and the critical public health frameworks essential for managing and preventing diseases at both population and individual levels. Driven by a commitment to advancing therapeutic options and improving patient outcomes, she honed her knowledge in both biostatistics and epidemiology. These skills have been foundational throughout her career, particularly in her roles focused on evidence generation and clinical research.
š Professional Endeavors
Throughout her distinguished career, Dr. Zhang has held senior roles at prominent pharmaceutical companies, demonstrating her expertise in medical affairs, clinical research, and strategic evidence generation.
- Sanofi, Cambridge, MA
As the Global Senior Medical Director in Immunology & Dermatology since 2018, Dr. Zhang has led impactful initiatives in Medical Evidence Generation within Global Medical Affairs. Her key achievements include winning Sanofiās āBest of Bestā award in 2023 and receiving a 1st Place Poster award at the American Academy of Dermatology (AAD) conference in 2024 for her workās scientific importance. Her leadership has propelled Sanofiās immunology initiatives, particularly through studies such as PEDISTAD and INFANTSTAD, which focus on disease modification and prevention of the atopic march.
- Apellis, Waltham, MA
In her tenure as Medical Director at Apellis from January 2017 to December 2017, Dr. Zhang was responsible for strategic planning and clinical development in hematology, overseeing Phase II and III studies in conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and autoimmune hemolytic anemia (AIHA). Her role included extensive interaction with thought leaders and the clinical team to design and optimize trial strategies.
- Biogen, Cambridge, MA
From 2009 to 2016, Dr. Zhang held several pivotal roles at Biogen, advancing from Medical Director in Global Medical Affairs to leading biostatistical teams for key drug programs like Tecfidera. She worked on Tysabriās lifecycle management, supporting clinical trial design, data generation, and publication strategies, especially in multiple sclerosis (MS). Her expertise in biostatistics and clinical research design strengthened Biogenās data-driven approaches, particularly in Phase III and IV clinical trials.
- PAREXEL International, Lowell, MA
Dr. Zhang worked as a Senior Biostatistician at PAREXEL from 2007 to 2009, leading biostatistical tasks across diverse therapeutic areas, including oncology, CNS disorders, and cardiovascular disease. Her meticulous approach ensured the quality and accuracy of statistical reports for clinical trials, contributing to numerous successful projects within the biostatistics team.
- New England Research Institutes, Watertown, MA
Early in her career, Dr. Zhang served as an Associate Research Scientist at NERI from 2000 to 2007, where she conducted critical statistical analyses for clinical research, laying the groundwork for her later expertise in biostatistics and clinical study design.
š” Contributions and Research Focus
Dr. Zhangās research has centered around dermatology, immunology, and hematology. At Sanofi, her work in immunology has led to groundbreaking insights on skin barrier integrity and neuroimmune function, providing essential evidence for the prevention of atopic march. She has also driven significant advancements in real-world evidence generation, particularly in cross-functional collaboration with global market access and regulatory teams, demonstrating her strategic alignment with organizational goals and patient needs.
š Accolades and Recognition
Dr. Zhangās achievements have earned her numerous accolades, including the prestigious āBest of Bestā award at Sanofi in 2023. In addition, she received 1st Place at the AAD 2024 Poster Award for her study on skin barrier health. Her work has also made her one of the most-read and cited authors in Allergy and Pediatric Dermatology in 2024, underscoring her impact and visibility in her field.
š Impact and Influence
Through her extensive collaborations, Dr. Zhang has influenced clinical practices and regulatory frameworks worldwide. Her involvement in key study proposals and evidence generation initiatives has significantly impacted the medical communityās understanding of dermatological conditions. Her efforts in strategic planning, data generation, and cross-functional teamwork have positioned her as an influential figure in dermatology and immunology, particularly in advancing therapies that meet rigorous safety and efficacy standards.
š± Legacy and Future Contributions
Dr. Zhangās legacy lies in her innovative approach to medical evidence generation and her unwavering commitment to patient-centered research. Her leadership in studies such as PEDISTAD and INFANTSTAD has set new standards for clinical research in dermatology and immunology. As she continues her work at Sanofi, Dr. Zhangās contributions promise to expand the understanding and treatment of complex immunological conditions, impacting healthcare practices on a global scale.
Through her career, Dr. Zhang has exemplified excellence, dedication, and a strategic vision, ensuring her place as a respected leader in the pharmaceutical and clinical research sectors. Her ongoing work will undoubtedly continue to shape medical innovations and patient care improvements, leaving a lasting legacy in the fields of immunology and dermatology.